The AHA today expressed support for and urged all senators to support an amendment to the Labor, Health and Human Services and Education appropriations bill that would help address the out-of-control cost of prescription drugs. Offered by Sens. Dick Durbin (D-IL) and Chuck Grassley (R-IA), amendment #3787 would provide funding to enable HHS to require disclosure of drug pricing information in direct-to-consumer advertising. “DTC advertising has the potential to lead to overutilization of high-cost prescription drugs, including when lower-cost but equally effective options may be available,” AHA wrote in a letter to senators. “This is contributing to the unsustainable rate of growth in prescription drug spending, which is consuming a bigger portion of health care dollars each year. Requiring disclosure of drug pricing information in DTC advertising will meaningfully enhance drug pricing transparency and provide useful information for consumers as they engage in discussions with their providers about the best treatment options for their individual health care needs.”

Related News Articles

Headline
Sens. Lamar Alexander, R-Tenn., and Patty Murray, D-Wash., today introduced the Lower Health Care Costs Act (S.1895), legislation to prevent surprise medical…
Headline
The Senate Committee on Health, Education, Labor and Pensions today held a hearing on the Lower Health Care Costs Act, its draft legislation to prevent…
Headline
In an evaluation of 49 top-selling brand-name drugs, 28 of the drugs available since 2012 saw an increase in insurer and out-of-pocket costs of more than 50…
Headline
Eight national organizations representing health care, business and coverage providers, including the AHA, yesterday urged Congress to quickly establish a…
Headline
Ways and Means Committee Chairman Richard Neal, D-Mass., and Energy and Commerce Committee Chairman Frank Pallone Jr., D-N.J., along with Ranking Members Kevin…
Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on seven bills aimed at improving transparency in the drug supply chain to lower…